Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Genocea Biosciences Inc.
DescriptionT cell vaccine consisting of the infected cell polypeptide 4 (ICP4) and gD2 antigens from herpes simplex virus-2 (HSV-2) combined with the saponin-derivative adjuvant Matrix-M2
Molecular Target Infected cell polypeptide 4 (ICP4)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationHerpes simplex virus (HSV)
Indication DetailsTreat genital herpes; Treat herpes simplex virus type 2 (HSV-2) infection
Regulatory Designation
PartnerNovavax Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today